StockNews.AI

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

StockNews.AI • 2 hours

N/A
High Materiality8/10

Information

BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a ...

Original source

AI Summary

Tiziana Life Sciences is raising $8 million through a direct offering of shares priced at $1.25 each to fund its Phase 2 trials of foralumab, an innovative treatment for Multiple Sclerosis. The strong commitment from executives purchasing shares suggests increased confidence in the company's clinical prospects and potential breakthroughs.

Sentiment Rationale

Raising funds for clinical trials usually signals positive market sentiment, especially with executive share purchases indicating strong insider confidence.

Trading Thesis

TLSA could see upward price movement as clinical trial progress is funded.

Market-Moving

  • CEO and Executive Chairman purchasing shares signals strong executive confidence.
  • Direct offering enables crucial funding for clinical trials, impacting future valuations.
  • Warrants may lead to further dilution or capital influx, affecting share prices.

Key Facts

  • Tiziana conducts a direct offering of 6.4 million shares at $1.25 each.
  • Company expects gross proceeds of $8 million from the offering.
  • Proceeds will fund Phase 2 trials for foralumab in MS patients.
  • Key executives purchase shares, reflecting confidence in the company.
  • Warrants are included, potentially raising an additional $9.6 million.

Companies Mentioned

  • Tiziana Life Sciences (TLSA): Offering supports clinical trials that could drive stock price.

Corporate Developments

The announcement falls under Corporate Developments as it directly involves capital raising to fund key clinical trials, crucial for Tiziana's growth trajectory. This funding is pivotal, impacting product timelines and potential revenues.

Tiziana Life Sciences Announces $17.6 Million Registered Direct Offering

BOSTON, Jan. 16, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a biotechnology firm specializing in immunotherapy, has recently announced the pricing of a registered direct offering to raise approximately $17.6 million. The company will issue 6,400,000 ordinary shares at a price of $1.25 per share. This offering is made exclusively to members of senior management and existing shareholders without the involvement of an underwriter or placement agent.

Details of the Offering

The total gross proceeds from this offering are estimated at $8.0 million, before deducting the estimated expenses related to the offering. Each subscriber will also receive one warrant, allowing them to purchase an additional share at a price of $1.50 until July 16, 2026, potentially adding up to an additional $9.6 million in gross proceeds. The offering's closing is anticipated for January 16, 2026, pending standard closing conditions.

  • Shares Offered: 6,400,000 ordinary shares
  • Offering Price: $1.25 per share
  • Total Gross Proceeds from Offering: $8.0 million
  • Potential Additional Proceeds from Warrants: up to $9.6 million
  • Closing Date: January 16, 2026

Leadership Investment Highlights

Tiziana’s Chief Executive Officer, Ivor Elrifi, has personally invested in this round, purchasing 2,400,000 ordinary shares, which increases his total holdings to 2,757,848 shares. Additionally, Executive Chairman and Founder Gabriele Cerrone acquired 1,600,000 shares, bringing his total to 44,974,830 shares.

Use of Proceeds

The funds raised will facilitate the company’s ongoing clinical trials. Specifically, the proceeds will support the completion of its Phase 2 na-SPMS and MSA clinical trials, enabling Tiziana to reach critical top-line data readouts. Gabriele Cerrone expressed gratitude to shareholders, stating, “Your belief in Tiziana Life Sciences has been instrumental as we push forward to topline data in our clinical trials in na-SPMS and MSA."

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is Tiziana’s lead product. It is being developed to stimulate T regulatory cells via intranasal administration. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) are being treated and have shown either improvement or stability within six months. Foralumab is currently the only fully human anti-CD3 mAb in clinical development.

Company Overview

Tiziana Life Sciences is recognized as a clinical-stage biopharmaceutical company dedicated to pioneering innovative therapies. The firm is utilizing transformative drug delivery technologies to enable new routes for immunotherapy. Their proprietary nasal delivery system shows promise for enhancing efficacy, safety, and tolerability compared to traditional intravenous treatments.

For further inquiries regarding Tiziana Life Sciences and its pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements, reflecting Tiziana’s expectations and projections. Words such as 'anticipates,' 'expects,' 'intends,' and similar expressions denote forward-looking statements. Actual results may vary due to various factors. Consequently, the company advises stakeholders to consider these risks when evaluating the forward-looking statements made in this announcement.

Related News